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CpG island arrays represent a high-throughput epigenomic discovery platform to identify global disease-specific promoter
hypermethylation candidates along bladder cancer progression. DNA obtained from 10 pairs of invasive bladder tumours were
profiled vs their respective normal urothelium using differential methylation hybridisation on custom-made CpG arrays (n¼12288
clones). Promoter hypermethylation of 84 clones was simultaneously shown in at least 70% of the tumours. SOX9 was selected for
further validation by bisulphite genomic sequencing and methylation-specific polymerase chain reaction in bladder cancer cells
(n¼11) and primary bladder tumours (n¼101). Hypermethylation was observed in bladder cancer cells and associated with lack
of gene expression, being restored in vitro by a demethylating agent. In primary bladder tumours, SOX9 hypermethylation was present
in 56.4% of the cases. Moreover, SOX9 hypermethylation was significantly associated with tumour grade and overall survival. Thus,
this high-throughput epigenomic strategy has served to identify novel hypermethylated candidates in bladder cancer. In vitro analyses
supported the role of methylation in silencing SOX9 gene. The association of SOX9 hypermethylation with tumour progression and
clinical outcome suggests its relevant clinical implications at stratifying patients affected with bladder cancer.
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Epigenetic changes and genetic mutations contribute significantly
to the onset of human malignancies (Jones and Baylin, 2002;
Feinberg et al, 2006). The most common epigenetic event in the
human genome is the addition of methyl groups to the carbon-5
position of cytosine nucleotides (Costello et al, 2000; Esteller et al,
2001; Esteller, 2002; Jones and Baylin, 2002; Feinberg et al, 2006).
CpG islands are present in one-half of the human genes, and
typically overlap with promoters and first exons of genes (Costello
et al, 2000; Esteller et al, 2001; Esteller, 2002; Jones and Baylin,
2002; Feinberg et al, 2006). Hypermethylation of CpG islands is
frequently associated with inappropriate transcriptional silencing
of critical genes including tumour suppressors (Costello et al,
2000; Esteller et al, 2001; Esteller, 2002; Jones and Baylin, 2002;
Feinberg et al, 2006). Transcriptional inactivation by CpG island
promoter hypermethylation is a well-established mechanism for gene
silencing in bladder cancer (Cordon-Cardo et al, 2000; Muto et al,
2000; Lee et al, 2001; Markl et al, 2001; Stoehr et al,2 0 0 4 ;C a t t oet al,
2005; Chapman et al, 2005; Kim et al, 2005; Marsit et al, 2005; Wolff
et al, 2005; Urakami et al, 2006). Genes reported to be epigenetically
inactivated by hypermethylation in bladder cancer include p16
INK4a,
CDKN2A, RUNX3 or RASSF1, among others (Cordon-Cardo et al,
2000; Muto et al,2 0 0 0 ;L e eet al, 2001; Markl et al, 2001; Stoehr et al,
2004; Catto et al, 2005; Chapman et al, 2005; Kim et al, 2005; Marsit
et al, 2005; Wolff et al, 2005; Urakami et al, 2006).
CpG island arrays represent a high-throughput technology for the
discovery of CpG island loci frequently hypermethylated during
disease progression (Yan et al, 2000; Ching et al,2 0 0 5 ) .G e n e
profiling analyses of cancer cells after exposure to demethylating
agents may also uncover critical genes susceptible to be epigeneti-
cally silenced (Liang et al, 2002). Using a high-throughput
epigenomic approach with CpG arrays, we identify novel candidates
such as SOX9, presenting CpG island promoter hypermethylation in
bladder cancer. To the best of our knowledge, SOX9 had not been
reported to be epigenetically modified, nor differentially expressed in
bladder malignancies. In bladder cancer cell lines, the low expression
of SOX9 was restored by a demethylating agent in methylated cancer
cells. Furthermore, SOX9 promoter hypermethylation was frequently
found in bladder tumours. Moreover, SOX9 methylation was
associated with tumour grade and overall survival of bladder cancer
patients. These are relevant findings not only as they relate to cancer
progression but also for their utility in the clinical management of
patients affected by uroepithelial neoplasias.
METHODS
Tumour samples, cell lines, genomic DNA and RNA
extraction
Following IRB-approved protocols at MSKCC, primary bladder
tumours and paired normal urothelium were frozen in liquid
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snitrogen immediately after resection and stored at  801C until
processing. Bladder tissues embedded in OCT were macrodissected
to ensure a minimum of 75% of tumour or normal urothelium
counterpart cell subpopulations (Sanchez-Carbayo et al, 2006).
Genomic DNA was extracted using a non-organic method (Oncor,
Gaithersburg, MD, USA). Total RNA was isolated in two steps
using TRIzol (Life Technologies, Carlsbad, CA, USA), followed by
RNeasy purification (Qiagen, Valencia, CA, USA). DNA and RNA
quality was evaluated based on 260/280 ratios of absorbances and
the integrity was also checked by gel electrophoresis analysis using
the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA,
USA). For CpG methylation arrays, invasive bladder tumours
(n¼10) were compared to their paired normal urothelium. An
independent series of 101 bladder tumours (non-muscle invasive
(n¼56): pTa (n¼24), pT1 (n¼32); and muscle invasive (n¼45):
pT2 (n¼16), pT3 (n¼25), pT4 (n¼4)) was utilised to validate the
relevance of methylation candidates in bladder cancer progression
(Sanchez-Carbayo et al, 2006). Human bladder cancer cell lines
(n¼11) were obtained from the American Type Culture Collection
(Rockland, MD, USA) (Sanchez-Carbayo et al, 2002) and from the
European Collection of Cell Cultures (Salisbury, United Kingdom).
This set of cell lines included RT4, 5637, J82, T24, UM-UC-3,
HT1376, HT-1197, TCCSUP, ScaBER, SW780 and RT112.
CpG island arrays
Hypermethylation patterns of genomic DNA obtained from 10
pairs of bladder tumours were profiled vs their respective normal
urothelium using differential methylation hybridisation as pre-
viously reported (Yan et al, 2002; Adrien et al, 2006). A panel of
12288 CpG island clones was created from the CGI genomic library
from Cross et al, 1994, as part of the Human Genome Mapping
Project Resource Center (Heisler et al, 2005). Inserts from this CGI
library were polymerase chain reaction (PCR)-amplified, purified
by ethanol precipitation and then arrayed onto glass microscope
slides by a specialised robot designed and created at Albert
Einstein College of Medicine (Cheung et al, 1999; Adrien et al,
2006). The Differential Methylation Hybridisation (DMH) techni-
que was carried out as previously described (Yan et al, 2002).
Briefly, genomic DNA was initially digested with the four-base
(TT^AA) restriction enzyme MseIa t3 7 1C. This digestion
restricted most genomic DNA into fragments less than 200bp in
length, and left the GC-rich CpG islands relatively intact.
Experimental DNA fragments were ligated to linker primers using
the FastLink DNA ligation kit (Epicentre, Madison, WI, USA).
Samples were then digested with two methylation-sensitive
restriction enzymes (BstUI and HpaII) to increase coverage of
the genome and to ensure complete digestion. The resulting DNA
digests were purified and subsequently amplified by PCR. Using
this approach, genomic DNA fragments containing unmethylated
CpG sites in one sample (e.g. the reference normal urothelium
specimen) were degraded by restriction digests and not be
amplified. However, corresponding DNA fragments in the other
sample (the bladder tumour specimen) that contain methylated
restriction sites were protected from enzyme digestion and
subsequently amplified by PCR. Differentially methylated se-
quences were identified by comparing hybridisation signals
between fluorescently labelled tumour (Cy5) and reference (Cy3)
amplicons when hybridised to the CpG microarray. Fluorescent
labelling of DNA amplicons was carried out using the Klenow
fragment of DNA polymerase (Fisher, Pittsburg, PA, USA) with
random hexamers (Invitrogen, Carlsbad, CA, USA). Hybridisation
to CpG arrays was carried out overnight at 501C in a buffer
containing 30% formamide, 3  SSC, 0.75% SDS and 100ng of
human Cot-1 DNA. Following hybridisation, slides were briefly
washed with a solution of 1  SSC, 0.1% SDS, then washed for
20min at room temperature in 0.2  SSC, 0.1% SDS and 20min at
room temperature in 0.1  SSC (without SDS). Slides were
immediately dried as before and scanned using the GenePix
4000A microarray scanner (Molecular Devices, Sunnyvale, CA,
USA).
Methylation analyses of the promoter of SOX9
The CpG island methylation status of this gene was analysed by
two PCR analysis strategies of bisulphite-modified genomic DNA,
which induces chemical conversion of unmethylated, but not
methylated, cytosine to uracil. First, methylation status was
analysed by genomic sequencing of both strands of their
promoters after bisulphite treatment of genomic DNA of at least
eight clones per each of the bladder cancer cell lines, as previously
reported (Paz et al, 2003). Confirmation on at least two
independent clones was required to assign methylation sites. A
second strategy used methylation-specific PCR (MS-PCR) with
primers specific for either the methylated or the modified
unmethylated DNA. Primer sequences for bisulphite sequencing
and unmethylated and methylated reactions were designed
encompassing their transcription start sites distant at 723bp
before the ATG starting codon. Table 1 summarises primers,
annealing temperatures and conditions for both approaches. DNA
from normal lymphocytes treated in vitro (IVD) with SssI
methyltransferase was used as a positive control for methylated
alleles. DNA from normal lymphocytes was used as a positive
control for unmethylated alleles. PCR products were loaded onto
nondenaturing 2% agarose gels, stained with ethidium bromide
and visualised under an ultraviolet transilluminator.
Analysis of SOX9 expression in bladder cancer cell lines
Cell lines were treated with 1 and 5mM 5-AZA-20-deoxycytidine
(AZA; Sigma, St Louis, MO, USA) for 72h to achieve demethyla-
tion (Herman and Baylin, 2003; Paz et al, 2003). RNA was isolated
using RNeasy kit from Qiagen (Life Technologies, Gaithersburg,
MD, USA). RNA (1mg) was reverse-transcribed using AMV
Reverse Transcriptase (Promega, Madison, WI, USA) and ampli-
fied using specific primers and conditions for SOX9 (Table 1). PCR
was performed using a final volume of 15ml containing 1  PCR
Ecostart buffer (Ecogen, Barcelona, Spain), 1.5mM of MgCl2,
0.2mM of dNTP, 0.25mM of each primer and 1.5U of Ecostart Taq
polymerase (Ecogen). For PCR amplification, 0.4mg of cDNA was
utilised. Reverse transcription polymerase chain reaction (RT—
PCR) primers were designed between different exons and
encompassing large introns to avoid any amplification of genomic
DNA. Glyceraldehyde-3-phosphate dehydrogenase was used as an
Table 1 Primer sequences and PCR conditions for bisulphite sequencing (SEQ), methylation- (MSP) and unmethylation-specific PCR (USP) and RT–PCR
for SOX9
Sense primer (50-30) Antisense primer (50-30)
Product
size (bp)
Annealing temperature
(PCR cycles)
SEQ GGGGTTGGAGAATGATTTGTTAGAG TCTAAACTAAAATCTACCCCCACCTC 434 62 (40)
MSP GGTAGGTAGGTTCGTTTTAGGC TCTCTCCGCGACACCGAAAA 152 58 (34)
USP GTAGGTAGGTAGGTTTGTTTTAGGT CTCTCTCCACAACACCAAAAACT 152 58 (34)
RT–PCR AGTACCCGCACTTGCACAAC CGTTCTTCACCGACTTCCTC 178 60 (25)
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sinternal control to ensure cDNA quality and loading accuracy. The
amplification products were resolved by 2% agarose gel electro-
phoresis and visualised by ethidium bromide staining. Cell lysates
for protein analysis were analysed by western blotting using an
anti-SOX-9 antibody (goat polyclonal; BD, 1/250 dilution). Equal
loading was tested by re-probing with an antibody against human
a-tubulin (mouse monoclonal; Sigma, Saint Louis, MI, 1/4000
dilution). Gels were cast using the Miniprotean 3 system (Biorad,
Hercules, CA, USA) and developed using ECL immunodetection
reagents (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Immunofluorescence
Cells were grown on coverslips in P6 dishes, fixed in 4%
formaldehyde and fluorescently stained (Herman and Baylin,
2003; Paz et al, 2003). To monitor AZA exposure, cells were stained
for SOX9 at 1/400 dilution for 45min, using the antibody
mentioned above. The secondary antibody was used at 1/250
dilution. Confocal optical sections were obtained using a Leica TCS
SP microscope (Leica Microsystems, Wetzlar, Germany) equipped
with krypton and argon lasers. Images were acquired and
processed using the Leica LCS Lite software.
Statistical analysis
Associations among methylation patterns of SOX9 with clinico-
pathological variables such as tumour stage and tumour grade
were evaluated using nonparametric Wilcoxon–Mann–Whitney
and Kruskall–Wallis tests (Dawson-Saunders and Trapp, 1994).
Associations of methylation patterns with survival were evaluated
in those cases for which follow-up information were available,
using the log-rank test (Dawson-Saunders and Trapp, 1994).
Overall survival time was defined as the years elapsed between
surgery and death from disease (or the last follow-up date).
Patients who were alive at the last follow-up or lost were censored.
Survival curves were plotted using Kaplan–Meier methodology.
Statistical analyses were performed using the SPSS statistical
package (version 8.0) (SPSS Inc., Chicago, IL, USA).
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MAMDC1 14q21.3 7
SOX9 17q24.3–q25.1 7
INT4 11q13.5 7
CTNNAL1 9q31.2 7
PMF1 1q12 7
MEIS2 15q14 7
VIPR2 7p22.3 7
ZNF483 9q31.3 7
CMKOR1 2q37.3 7
LRRC33 3q29 7
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TRH 3q13.3–q21 8
PPP2CA 5q31.1 8
RFX4 12q24 8
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MARK3 14q32.3 8
CHMR3 1q41–q44 8
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Figure 1 CpG arrays. (A) Quality control: the relative percentage of methylated and unmethylated genes was similar among the pairs of bladder tumours
and normal urothelium samples under study. (B) CpG island arrays identify hypermethylated candidates in patients with bladder cancer. (C) Summary of
known genes among the 84 clones simultaneously hypermethylated in 7 out of 10 samples under analysis. The number of cases found differentially
expressed with a Cy5/Cy3 ratio higher than 2 for these genes are also indicated.
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sRESULTS
Identification of methylated candidates in bladder cancer
progression using CpG island arrays
For 10 bladder cancer patients, differential methylation hybridisa-
tion was utilised on a CpG island microarray to identify aberrantly
methylated genes in advanced bladder tumour specimens (Cy5) as
compared to their corresponding normal urothelium counterpart
(Cy3). Among the 12288 CpG islands analysed, half of them
provided informative results. The similar rates of hypermethylated
and informative clones among the 10 pairs of bladder tumours vs
their normal urothelium supported a similar and optimal
performance of the DNA handling, labelling and hybridisation of
the CpG island arrays (Figure 1A). Between 511 and 1186 clones
were identified to be individually hypermethylated in each tumour
sample relative to the corresponding normal urothelium tissue,
based on a Cy5/Cy3 ratio of 2.0 or greater (Figure 1A). Among the
12288 CpG island clones, 84 were shown to be hypermethylated in
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Figure 2 Analysis of CpG island methylation status of the promoter of SOX9 by bisulphite genomic sequencing in bladder human cancer cell lines (n¼11;
including nonmuscle invasive, invasive, metastatic transitional and squamous cells). The upper part indicates the nucleotide sequences of the CpG island
region analysed by bisulphite sequencing, sequencing primers highlighted in yellow and red and the area amplified in the chromatograms in blue. The mid-
section shows a schematic depiction of the SOX9 CpG islands around the transcription start sites. CpG dinucleotides are represented in squares. The
presence of ‘Cs’ in the dinucleotide CpG reflects methylated cytosines (black squares), while the presence of ‘Ts’ in the dinucleotide CpG reflects
unmethylated cytosines (white squares). Cell lines with black squares indicate the presence of methylation confirmed in at least two of the clones that were
sequenced for each of the cell lines under analyses. The bottom part displays representative examples of the chromatograms obtained by bisulphite genomic
sequencing of human cancer cell lines (a magnified boxed fragment is displayed). Normal lymphocytes (NL) were used as a negative sequencing control.
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their respective normal urothelium (Figure 1B). Figure 1C
summarises known genes among hypermethylated gene promoters
in bladder cancer, indicating the number of cases found
differentially methylated with a Cy5/Cy3 ratio higher than 2 for
these genes. A complete expanded version of the 84 clones is
provided as Supplementary Table 1. Among these 84 hypermethy-
lated clones with a Cy5/Cy3 ratio higher than 2.0 in the tumour
specimen of at least 7 of the 10 patients, SOX9 was selected for
further validation analyses. This gene was chosen once we
observed a significant statistical association of its decreasing
transcript levels with increasing tumour stage (Po0.005) after
analysing a previously reported transcript profiling series of our
group (Sanchez-Carbayo et al, 2006).
SOX9 CpG island hypermethylation and its association
with transcriptional gene silencing in bladder cancer cell
lines
SOX9 was tested to be a candidate gene for hypermethylation-
associated inactivation in bladder cancer cells. Enriched 50-CpG
islands were found to be located around their transcription start
sites, supporting their susceptibility to be epigenetically modified.
To assess their methylation status, 11 human bladder cancer cell
lines were initially screened using bisulphite genomic sequencing
and MS-PCR targeted to the areas surrounding their transcription
start sites. Bisulphite sequencing of these cell lines revealed CpG
island methylation for SOX9 (Figure 2). Among the normal tissues
analysed, lymphocytes (NL) and urothelium were found unmethy-
lated at the SOX9 CpG island promoter (Figure 2).
Having observed promoter hypermethylation in bladder cancer
cell lines by bisulphite sequencing, specific MS-PCR was
performed for SOX9 (Figure 3). Methylation patterns observed
by bisulphite sequencing highly correlated with the results
obtained by MS-PCR, with differences attributable to the use of
primers in these techniques encompassing slightly different areas
around the transcription start sites for both strategies (Figure 2).
Methylation analyses were then linked to transcript and protein
expression estimates of the gene under study. The association
between these epigenetic aberrations and putative transcriptional
inactivation of this gene was initially assessed at the RNA and
protein levels. Bladder cancer cell lines hypermethylated for SOX9
showed low transcript and protein expression as revealed by
RT–PCR and western blot analyses (Figure 3).
Treatment of methylated and unmethylated bladder cancer cell
lines with a DNA-demethylating agent served to further link SOX9
hypermethylation and gene silencing. Exposure of methylated
bladder cancer cell lines to the demethylating drug, AZA, restored
expression of SOX9 at the transcript level in the J82 cell line. RT4
was used as the control cell line to assess the specificity of AZA
exposure, but not to modify gene expression of this candidate gene
in unmethylated bladder cancer cells (Figure 4). Western blot and
immunofluorescence analyses were performed to confirm that
protein expression was also restored after AZA exposure. Overall,
the results indicated a high correlation of methylation data with
gene expression, observations especially supported by AZA
reactivation analyses.
SOX9 is frequently hypermethylated in primary bladder
tumours, and associated with clinicopathological variables
Once the functional consequences of SOX9 CpG island hyper-
methylation were determined in vitro, it was tested whether
hypermethylation of this gene was cancer-specific. Comparison of
methylation of bladder tumours and their respective pairs of
normal urothelium was analysed on an independent set of 10 cases
for which paired normal urothelium DNA was available. Methyla-
tion was found in 70% of the bladder tumours and 10% of the
normal urothelium tested. Illustrative examples of MS-PCR results
among bladder tumours and paired normal urothelium are shown
in Figure 5A. The relevance of their methylation in human clinical
material was further analysed by MS-PCR in an independent large
set of 101 primary bladder tumours. Hypermethylation patterns of
this gene among these samples can be assessed in Figure 5B.
Overall, SOX9 CpG island hypermethylation was respectively found
in 56.4% of the cases (57/101). The next analyses dealt with
evaluating the link between the hypermethylation status of SOX9
and clinicopathological variables of bladder cancer patients, as
summarised in Figure 5B. Overall, tumours displaying high grade
were more frequently methylated than those with low grade. A
significant association of hypermethylation with tumour grade was
found for SOX9 (Mann–Whitney, P¼0.032). Interestingly, SOX9
hypermethylation was significantly associated with shorter overall
survival (log-rank, P¼0.025; Figure 5C). Therefore, SOX9
SOX-9
U
MSP
BS-Seq
RT–PCR
GAPDH
WB
Tubulin
MU MU MU MU MU MU MU M U MU MU M UMU MU M
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UM-UC-3
HT-1197
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TCCSUP
T-24
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RT4
5637
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NL IVD H2O
Figure 3 CpG island methylation is associated with gene silencing of SOX9. The upper part shows methylation-specific PCRs for SOX9 in human bladder
cancer cell lines. The presence of a PCR band under the lane M indicates a methylated gene, while the presence of a PCR band under the lane U indicates an
unmethylated gene. Normal lymphocytes (NL) and in vitro-methylated DNA (IVD) were used as negative and positive controls for unmethylated and
methylated PCRs, respectively. Sequencing information is included as well, highlighting methylated cell lines by genome sequencing in dark grey. Reverse
transcription polymerase chain reaction analysis of SOX9 expression is displayed. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) transcript
expression was used as a transcript loading control. Western blot analysis of protein expression is also shown. Tubulin expression was used as a
protein loading control. The hypermethylated cell lines show relatively low transcript and protein expression of the coded protein as compared to
unmethylated cell lines.
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shypermethylation was identified to be a likely predictor of poor
outcome.
DISCUSSION
The use of high-throughput profiling approaches is accelerating
the discovery of genetic and epigenetic events associated with
tumorigenesis and tumour progression. This study represents the
first report describing the use of CpG island arrays as a means to
comprehensively identify hypermethylation candidates in bladder
cancer. By using a comprehensive approach, hypermethylation of
novel genes was identified along bladder cancer progression due to
the strategy of comparing bladder tumours and normal urothelium
counterparts. Among the genes showing twofold hypermethylation
in at least 7 of 10 cancers, SOX9 gene was chosen for further
analysis. To our knowledge, there was no data suggesting that
SOX9 could be epigenetically modified by methylation in human
cancer. This gene was chosen once we observed significant
statistical associations of its decreasing transcript levels with
increasing tumour stage (Po0.005) after analysing a previously
reported transcript profiling data of our group (Sanchez-Carbayo
et al, 2006), suggesting their involvement in bladder cancer
progression. This clinical observation excluded the need to
estimate multiple testing and false discovery thresholds for
SOX9, a common strategy undertaken for candidate selection in
high-throughput studies.
The consequences of CpG island hypermethylation of candidate
genes in bladder cancer progression need to be assessed from the
standpoint of mechanistic, biological and translational implica-
tions. Mechanistically, it is important to evaluate the cellular
consequences of the methylation of the promoter of SOX9 in
bladder cancer cells. Several techniques were utilised to link
methylation analyses with expression estimates of the gene under
study. Methylation status and expression results of SOX9
correlated to high extent among a variety of bladder cell lines
representing the spectrum of bladder cancer progression in vitro.
AZA exposure experiments confirmed the impact of methylation
in the expression of this gene by specifically restoring their
transcript and protein expression in methylated bladder cancer
cells. Overall, in vitro analyses demonstrated that the expression of
SOX9 is aberrantly silenced by CpG island promoter hypermethy-
lation in bladder cancer, observations especially supported by AZA
reactivation analyses.
To the best of our knowledge, SOX9, the gene identified in the
present report, had not been previously related to bladder cancer.
SOX9 is a transcription factor that is expressed in chondrocytes
and several tissues, including the central nervous and urogenital
systems (Huang et al, 2000; Soderstrom et al, 2002). SOX9 has been
shown to be relevant at distinguishing mesenchymal chondrosar-
coma from other small blue round cell tumours (Soderstrom et al,
2002; Wehrli et al, 2003) and at modulating retinoid-mediated
growth in breast cancer cells (Afonja et al, 2002). Growth and
tumorigenicity suppression associated with SOX9 has been found
in prostate, breast and colon cells (Afonja et al, 2002; Drivdahl
et al, 2004; Jay et al, 2005). The epigenetic silencing of SOX9 may
aid understanding as to how it contributes to tumorigenesis and
tumour progression in such types of neoplasias. Future studies are
also warranted to dissect such mechanisms in the context of
bladder cancer.
More importantly, the translational implications of the dis-
covery of the methylation of this novel candidate gene identified
by the CpG array have also been addressed in this work. CpG
arrays identified higher methylation rates of the potential
methylation candidate genes in tumour specimens as compared
to normal urothelium counterparts. It was then necessary to test
whether SOX9 methylation was a cancer-specific epigenetic event.
An independent set of 10 pairs of bladder tumours and normal
urothelium, similar to the set used for the discovery of explorative
analyses, was utilised to validate the presence of cancer-specific
methylation of SOX9 by an independent method, MS-PCR. SOX9
methylation was found with rates higher than 70% in bladder
tumours and lower than 20% in their normal urothelium
counterparts, an observation suggesting that SOX9 could be
methylated in a cancer-specific manner. Methylation in normal
urothelium by MS-PCR could be attributed to the presence of
mixed subpopulations to a certain extent detectable by a PCR-
based technique, or that methylation could be a very early cancer
epigenetic event, especially detectable in phenotypically normal
urothelium counterparts due to the field effect. The initial
RT-PCR
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J82
RT4
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RT4+AZA (5 M)
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Figure 4 The treatment with the demethylating agent AZA
reactivates gene expression of SOX9. The upper part displays the reverse
transcription polymerase chain reaction analysis of SOX9 expression.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression was
used as a transcript loading control. The hypermethylated J82 cell line
did not express SOX9, and restored SOX9 transcript expression after AZA
exposure. The mid-section shows western blot analysis of protein
expression. Tubulin expression was used as a protein loading control.
The hypermethylated cell line did not express the coded protein. The
treatment with the demethylating agent reactivated SOX9 protein
expression. The unmethylated RT4 cell line did not show changes in
transcript or protein expression. The bottom part displays immunofluo-
rescence analysis of SOX9 expression after AZA exposure. The methylated
cell line did not show any staining for the protein, while the unmethylated
ones showed its characteristic staining pattern.
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sdiscovery of this methylated candidate gene by comparing bladder
tumours and their respective normal urothelium counterparts on
the CpG arrays together with these observations on an indepen-
dent set of cases were consistent with the concept of cancer-
specific hypermethylation. This is a critical issue that requires to
be tested for any hypermethylated candidates since the CpG arrays
identified methylation higher in tumour specimens than in normal
counterparts, without necessarily implying this epigenetic event to
be cancer-specific.
It should be mentioned that several qualitative and quantitative
methodologies are available for the purpose of determining
methylation status of tumour specimens (Esteller, 2007). We
selected standard gel-based MS-PCR, which could be considered
appropriate enough for our descriptive analyses aiming at
distinguishing between methylated and unmethylated cases.
Considering the issue of tissue heterogeneity, only the complete
absence of a PCR band was reported as a negative result.
Quantitative RT–PCR methodologies are known to show their
main advantages for comparative quantitative methylation ana-
lyses especially in body fluids. MS-PCR analyses in bladder cancer
cell lines and independent sets of bladder tumours showed highly
varying hypermethylation rates. CpG arrays and MS-PCR in the
discovery and validation sets of 10 pairs of tumours and normal
urothelium revealed the presence of SOX9 methylation in at least
70% of the invasive cases analysed. Methylation rates were closer
to 60% in the larger series of bladder tumours, which confirmed
that SOX9 hypermethylation is a frequent event in bladder cancer.
Moreover, this independent set of 101 bladder tumours served
to explore the clinical relevance of the identified methylation
for SOX9.
The association of SOX9 hypermethylation with bladder cancer
progression can be justified as follows: first, the experimental
design of the discovery of this methylated candidate gene by
comparing invasive tumours vs their respective normal urothelium
associates it with bladder cancer progression, providing cancer
specificity to this candidate confirmed using independent sets of
pairs of tumours and normal urothelium; second, this gene was
selected based on its statistical association with tumour stage using
transcript profiling analyses of bladder tumours (Po0.005); third,
it was shown that methylation of SOX9 is a frequent event among
bladder tumours using an independent larger series of patients
with bladder cancer. The methylation rates of 55.3% of the
nonmuscle invasive cases showed that this epigenetic modification
is an early event in bladder cancer. Moreover, the significant
association of SOX9 methylation with clinicopathological tumour
grade and survival further supported their association with cancer
progression. Interestingly, the presence of SOX9 hypermethylation
was associated with overall survival, confirming its potential role
as a prognostic marker in the clinical management of patients
affected with uroepithelial tumours. Such finding meets concor-
dance with the knowledge of the involvement of this gene in
human solid neoplasias. Inactivation by hypermethylation of
SOX9, a gene reported to be a potential tumour suppressor, would
be justified to be a poor outcome prognosticator (Afonja et al,
2002; Wehrli et al, 2003; Drivdahl et al, 2004). Thus, the gene
identified in the present work represents a novel methylated
tumour suppressor candidate to be investigated in bladder cancer.
In addition to clinicopathological stratification of patients with
bladder cancer, a relevant translational point relates to treatment,
since it poses the potential use of demethylating agents such as 5-
azacytidine in bladder cancer, to reactivate CpG island-hyper-
methylated genes, as has been approved by the Food and Drug
Administration for a preleukemic disease, the myelodysplastic
syndrome (Esteller, 2007). In this new scenario, SOX9 represents a
candidate target gene supporting the potential use of this type of
drugs to achieve their demethylation and reactivation in bladder
tumours. Further research would identify target-specific demethy-
lating agents due to the complexity of epigenetic events along
tumour progression.
In summary, our study discovers novel hypermethylated
candidate genes in bladder cancer. It provides a mechanistic
explanation for the observed loss of SOX9 in uroepithelial
malignancies, demonstrating transcriptional silencing by promoter
CpG island hypermethylation in bladder cancer cell lines.
Although the ultimate consequences of its epigenetic inactivation
in the molecular biology of the tumour cell remain unknown, its
hypermethylation emerges as a strong indicator of tumour
progression and clinical outcome for bladder cancer patients.
These data should encourage further research into its downstream
biological impact in tumorigenesis and cancer progression and
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Figure 5 Association between SOX9 hypermethylation with cancer progression and clinical outcome in bladder tumours. (A) Representative pairs of
normal urothelium (NB) and primary bladder tumours (T) analysed by MS-PCR for SOX9. The presence of a PCR band under the lane M indicates a
methylated gene, while the presence of a PCR band under the lane U indicates an unmethylated gene. Normal lymphocytes (NL) and in vitro-methylated
DNA (IVD) are used as negative and positive controls for unmethylated and methylated PCRs, respectively. (B) Summary of the number of unmethylated
(U) and methylated (M) cases for SOX9 regarding their tumour stage and tumour grade. (C) Kaplan–Meier curve describing the association of SOX9
hypermethylation with poor overall survival.
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seventually as a potential therapeutic target to be addressed
following an epigenetic approach.
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